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MiOBJECTIVES This study sought to determine if plaque structural stress (PSS) and other plaque stress parameters are
increased in plaques that cause future major adverse cardiovascular events (MACE) and if incorporating these parameters
improves predictive capability of intravascular ultrasonography (IVUS).
BACKGROUND Less than 10% of coronary plaques identified as high-risk by intravascular imaging result in subsequent
MACE. Thus, more specific measurements of plaque vulnerability are required for effective risk stratification.
METHODS Propensity score matching in the PROSPECT (Providing Regional Observations to Study Predictors of Events
in the Coronary Tree) study plaque cohort resulted in 35 nonculprit lesions (NCL) associated with future MACE and 66
matched NCL that remained clinically silent. PSS was calculated by finite element analysis as the mechanical loading
within the plaque structure in the periluminal region.
RESULTS PSS was increased in the minimal luminal area (MLA) regions of NCL MACE versus no MACE plaques for all
plaques (PSS: 112.1  5.5 kPa vs. 90.4  3.3 kPa, respectively; p ¼ 0.001) and virtual histology thin-cap fibroatheromas
(VH-TCFAs) (PSS: 119.2  6.6 kPa vs. 95.8  5.0 kPa, respectively; p ¼ 0.005). However, PSS was heterogeneous over
short segments, and PSS heterogeneity index (HI) was markedly greater in NCL MACE than in no-MACE VH-TCFAs
(HI: 0.43  0.05 vs. 0.29  0.03, respectively; p ¼ 0.01). Inclusion of PSS in plaque assessment improved the
identification of NCLs that led to MACE, including in VH-TCFAs (p ¼ 0.03) and plaques with MLA #4 mm2 (p ¼ 0.03).
Incorporation of an HI further improved the ability of PSS to identify MACE NCLs in a variety of plaque subtypes including
VH-TCFA (p ¼ 0.001) and plaques with MLA #4 mm2 (p ¼ 0.002).
CONCLUSIONS PSS and variations in PSS are increased in the peri-MLA regions of plaques that lead to MACE.
Moreover, longitudinal heterogeneity in PSS is markedly increased in MACE plaques, especially VH-TCFAs, potentially
predisposing to plaque rupture. Incorporation of PSS and heterogeneity in PSS may improve the ability of IVUS to
predict MACE. (J Am Coll Cardiol Img 2019;-:-–-) © 2019 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2019.05.024
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AND ACRONYMS
FEA = finite element analysis
HI = heterogeneity index
MACE = major adverse
cardiovascular events
MLA = minimal luminal area
PB = plaque burden
PSS = plaque structural stress
VH-IVUS = virtual histology
intravascular ultrasonography
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C ardiovascular disease is a leadingcause of mortality worldwide (1),and most deaths are attributable to
ischemic heart disease. Techniques that can
identify coronary plaques at risk for adverse
events are therefore of particular interest.
Virtual histology intravascular ultrasonogra-
phy (VH-IVUS) can determine both plaque
size and composition, resulting in an
imaging-based plaque classification. PROS-
PECT (Providing Regional Observations to
Study Predictors of Events in the Coronary
Tree), the largest VH-IVUS study to date,
showed that minimal luminal area(MLA) #4.0 mm2, plaque burden (PB) $70% at the
MLA, and the presence of virtual histology thin-cap
fibroatheroma (VH-TCFA) were independent predic-
tors of nonculprit (NCL) future major adverse cardio-
vascular events (MACE) over a 3-year period (2). In
contrast, NCL nonfibroatheromas were rarely associ-
ated with MACE over the same interval (3). Subse-
quently both the VIVA (VH-IVUS in vulnerable
atherosclerosis) and the AtheroRemoIVUS (European
Collaborative Project on Inflammation and Vascular
Wall Remodeling in Atherosclerosis-Intravascular Ul-
trasound Study; NCT01789411) studies found that VH-
TCFA and PB $70% were associated with future
events (4,5). Although the consistency of all 3 pro-
spective studies validates these features to identify
higher risk plaques, <10% of NCL VH-TCFAs led to
MACE in all 3 studies, indicating that more specific
techniques are required to better characterize coro-
nary plaques.
Plaque structural stress (PSS) is the stress located
inside an atherosclerotic plaque due to plaque struc-
ture and composition, and is affected by vessel
expansion and stretch induced by arterial pressure.
PSS is linked to plaque rupture both ex and in vivo
(6,7), so incorporation of PSS into coronary plaque
assessment may improve the ability of imaging to
identify high-risk coronary plaques. Indeed, PSS is
increased in culprit plaques of patients presenting
with acute coronary syndrome (ACS) versus stable
angina (8) and in the peri-MLA region of those
showing rupture versus no rupture (9). PSS was
increased in NCL MACE plaques in the VIVA study
compared to no-MACE plaques with similar gray-scale; has received honoraria as speaker from Amaranth and Terumo
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stress measurements to be useful clinically they need
to be validated in larger multicenter studies, and
other stress-based parameters may be more predic-
tive of MACE than PSS alone. The current study aimed
to determine if a) PSS of plaques responsible for NCL
MACE in PROSPECT are increased compared to a
propensity-score-matched control population; b) if
other stress-based parameters were more discrimi-
natory; and (c) if incorporating different PSS param-
eters provides incremental prognostic information
over IVUS imaging alone.
METHODS
PATIENT RECRUITMENT. The protocol for the PROS-
PECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) study and
inclusion and exclusion criteria have already been
described (2) (Supplemental Appendix). Briefly, 697
patients with ACS were recruited across 37 U.S. and
European sites after undergoing successful percuta-
neous coronary intervention for all coronary lesions
responsible for the index event and completion of any
other planned interventions. A total of 623 patients
underwent 3-vessel gray-scale and VH-IVUS assess-
ment, and medication therapy after discharge was
followed according to guideline standards. Clinical
follow-up occurred at 30 days, 6 months, and annu-
ally for at least 2 years (median: 3.4 years).
VH-IVUS IMAGE ACQUISITION AND ANALYSIS.
VH-IVUS was performed in the left main stem and
proximal 6 to 8 cm of the major epicardial vessels
using a 20-MHz synthetic aperture array 3.2-F cath-
eter (Eagle Eye, In-Vision Gold, Volcano, Rancho
Cordova, California) with motorized catheter pull
back (0.5 mm per second) after the administration of
glycerin trinitrate. A plaque was defined as $3
consecutive frames with PB $40% and classified as
VH-TCFA, thick-cap fibroatheroma (VH-ThCFA),
pathological intimal thickening (VH-PIT), fibrotic
(VH-FT), or fibrocalcific plaque (VH-FCa). The MLA
was defined as the IVUS frame with the smallest
luminal area over the whole plaque. A lesion was
classified as having PB $70% if PB at the MLA site
was $70%. Analysis was performed off-line and was
not used for procedural guidance.; holds equity in Ancora, Cagent, Qool Therapeutics,
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FIGURE 1 Patient and Plaque Populations
PROSPECT population (697 patients)
Patients with gray-scale IVUS (3229 NCLs in 660 patients)
Non-culprit lesions with PB ≥60% (1087 lesions in 505 patients)
Candidate NCLs with MACE
(n = 35 lesions)
Candidate NCLs without MACE
(n = 384 lesions)
1:2 Propensity score matching






Patients with NCL MACE related to NCLs that were not identified at baseline or
without valid VH-IVUS data were eliminated from the analysis
If a patient has multiple NCLs:
1. Choose NCL with MACE
3. If multiple NCLs without MACE, choose the NCL with the greatest PB
2. If multiple NCL MACE in patient with multiple NCLs with PB ≥60%, choose NCL associated with the first NCL MACE
Schematic representation of patient and plaque populations included in the study. MACE ¼ major adverse cardiovascular event; NCL ¼ nonculprit lesion;
PB ¼ plaque burden; VH-IVUS ¼ virtual histology intravascular ultrasonography.
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CLINICAL ENDPOINTS AND DEFINITIONS. Indepen-
dent study monitors verified all data for case report
forms. The pre-specified primary endpoint was the
incidence of MACE defined as the composite of car-
diac death, cardiac arrest, myocardial infarction, or
hospitalization due to unstable or progressive angina
according to Braunwald unstable angina classification
and the Canadian Cardiovascular Society angina
classification. The primary endpoint was adjudicated
by a clinical events committee that had no knowledge
of other patient data. Clinical events were attributed
to culprit lesions or non-culprit lesions (NCL)
based on follow-up angiography. If angiography was
not performed, the event was classified as
indeterminate.
BIOMECHANICAL ANALYSIS. Vessel geometry and
plaque composition were extracted from radio-
frequency IVUS data and imported into dedicated
analysis software (proprietary code, MATLAB R2012b,
MathWorks, Inc, Natick, Massachusetts), allowing
construction of 8,182 VH-IVUS models. Briefly, each
VH-IVUS frame was segmented into its individualcomponents using an in-house MATLAB code
with the resulting segmented model undergoing dy-
namic 2D FEA simulations as described previously
(Supplemental Appendix). A 65-mm layer of fibrous
tissue was introduced during mesh generation to ac-
count for the limited axial resolution of VH-IVUS to
detect a fibrous cap between lumen and necrotic core/
dense calcium. Maximum principal stress was used to
indicate the critical mechanical conditions, the PSS,
with variations in PSS being the difference between
PSS in systole and that in diastole. As plaque desta-
bilization is a focal event, PSS across the whole pla-
que may not reflect PSS where plaque disruption
occurs. Therefore, PSS and variations in PSS in the
peri-MLA segments (z4 mm proximal and distal to
the MLA with PB $40%) were compared, as this rep-
resents extensive disease and where plaque disrup-
tion often occurs (9). The heterogeneity of PSS along
the length of each plaque was also examined as this
can amplify the effects of PSS or variations in PSS at
areas of fibrous cap weakness thereby promoting
plaque rupture. This was assessed by the heteroge-
neity index (HI), defined as the standard deviation of
TABLE 1 VH-IVUS Characteristics of MACE and No MACE Nonculprit Lesions
MACE (n ¼ 35) No MACE (n ¼ 66) p Value
Lesion phenotype
VH-TCFA 20/35 (57.1) 31/66 (47.0) 0.33
VH-ThCFA 12/35 (34.3) 26/66 (39.4) 0.61
VH-PIT 2/35 (5.7) 9/66 (13.6) 0.32
VH-FCa 1/35 (2.9) 0/66 (0.0) 0.35
VH-FT 0/35 (0.0) 0/66 (0.0) NA
VH-TCFA or VH-ThCFA 32/35 (91.4) 57/66 (86.4) 0.54
Plaque data
% NC volume 15.5 (9.0-21.5) 14.9 (8.8-23.1) 0.73
% DC volume 6.1 (2.7-9.8) 6.3 (3.6-9.4) 0.95
% FT volume 60.7 (54.5-65.9) 57.6 (53.7-62.0) 0.22
% FF volume 15.2 (10.9-22.5) 16.4 (10.2-23.2) 0.78
MLA site data
% NC CSA 13.9 (8.7-25.1) 16.6 (8.9-29.1) 0.44
% DC CSA 5.0 (2.3-10.9) 6.0 (2.0-11.4) 0.73
% FT CSA 61.1 (53.7-68.8) 58.7 (49.0-64.2) 0.11
% FF CSA 11.1 (7.0-22.0) 12.6 (5.8-22.2) 0.80
Values are n/N (%) or median (interquartile range).
CSA ¼ cross-sectional area; DC ¼ dense calcium; FT ¼ fibrous tissue; FF ¼ fibrofatty; FCa ¼ fibrocalcific;
NC ¼ necrotic core; MLA ¼ minimum luminal area; PIT ¼ pathological intimal thickening TCFA ¼ thin-cap
fibroatheroma; ThCFA ¼ thick-cap fibroatheroma.
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PSS divided by mean PSS or variations in PSS in the
area of interest.
STATISTICAL ANALYSIS. Propensity score matching
with a 1:2 ratio was used to identify NCL MACE and
no-MACE groups to minimize selection bias due to
differences in patient and lesion characteristics. Only
1 lesion per patient was selected, and only those pa-
tients with a PB $60% at the MLA were included,
because more than 85% of NCL MACE occurred in
lesions with a PB $60%. In patients with multiple
NCL, the lesion with the greatest PB was chosen.
However, PSS was also calculated for all VH-IVUS
frames with PB $40%. Both patient and lesion pa-
rameters were used in calculation of propensity
scores. Patient-level parameters included presence of
insulin-treated diabetes mellitus, history of percuta-
neous coronary intervention, age, and sex. Lesion-
level parameters included PB at the MLA, MLA, and
plaque classification (Supplemental Appendix). Pro-
pensity score matching generated 101 NCLs, 35 of
which led to future MACE (Figure 1). The remaining 66
NCLs formed the control group. The C-statistic was
0.887, and the Hosmer-Lemeshow test p value was
0.931, confirming good discrimination and goodness-
of-fit of the propensity score model. A total of 8,182
VH-IVUS frames were analyzed with a median of 66
(42 to 104) frames per plaque.
Data variables are median (quartile [Q]1 to Q3) and
were compared using the Mann-Whitney U test. As
each plaque had multiple VH-IVUS slices, a linearmixed-effects model was used to compare groups by
using a random effect for plaque and fixed effects for
group to account for clustering with results presented
as mean  SEM. All calculations were 2-tailed and a p
value <0.05 was considered statistically significant.
Receiver operating characteristic (ROC) curves
were calculated by plotting sensitivity versus
(1  specificity), allowing calculation of the area un-
der the curve (AUC) and the identification of PSS and
heterogeneity in PSS cutoff thresholds that best pre-
dicted future MACE. Each cutoff value was subse-
quently applied to categorize PSS and heterogeneity
in PSS into low and high groups, allowing generation
of time-to-event curves that incorporated these.
Time-to-event data are presented as Kaplan-Meier
estimates of cumulative hazard and were compared
using the log-rank method. Statistical analyses were
performed using both SPSS version19.0.0 software
(IBM, Armonk, New York) and R version 2.10.1 soft-
ware (R Foundation for Statistical Computing,
Vienna, Austria).
RESULTS
BASELINE PATIENT CHARACTERISTICS. A total of
101 patients were included in the analysis, 35 of
whom experienced a NCL MACE. Patient de-
mographics were similar between the 2 groups
(Supplemental Table 1). There were no significant
differences in rates of diabetes (28.6% vs. 19.7%,
respectively; p ¼ 0.31) or hypercholesterolemia
(53.6% vs. 49.2%, respectively; p ¼ 0.70). Initial
clinical presentation was also similar between the
MACE and no-MACE groups, with most patients
presenting with non–ST-segment elevation myocar-
dial infarction (68.6% vs. 72.7%, respectively;
p ¼ 0.66). Following treatment of culprit vessels,
patients began medical therapy according to local
guidelines. There were no significant differences
between the 2 groups for antiplatelet, statin,
angiotensin-converting enzyme inhibitor, or beta-
blocker therapy, either at discharge or follow-up
(Supplemental Table 2).
BASELINE NONCULPRIT LESION ANGIOGRAPHIC
AND IVUS CHARACTERISTICS. Vessels of patients
underwent quantitative angiographic coronary and
IVUS analysis. There were no significant differences
in the number of diseased vessels, defined as diam-
eter of stenosis on quantitative angiographic coro-
nary analysis >30%, or number of vessels with lesions
(Supplemental Table 3). Gray-scale IVUS analysis
revealed some differences between the 2 groups.
Echolucent plaques were more frequent in the MACE
group (34.3% vs. 12.1%, respectively; p ¼ 0.008) but
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(A) VH-IVUS frame and PSS band plots in systole and in diastole. (B) Longitudinal variations of PSS in no-MACE and MACE plaques with examples of VH-IVUS images
and corresponding PSS band plots. PSS ¼ plaque structural stress; other abbreviations as in Figure 1.
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PSS and variations in PSS at (A) all plaques, (B) VH-TCFAs, (C) Plaques with MLA #4 mm2, (D) plaques with PB $70% at the MLA, (E)
VH-TCFA þMLA#4mm2, and (F) VH-TCFA þ PB$70%. p < 0.05. MLA ¼minimal luminal area, PB¼ plaque burden, PSS ¼ plaque structural
stress, VH-TCFA ¼ virtual histology thin-cap fibroatheroma; other abbreviations as in Figure 1.
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with similar NCL length (30.4 mm [range 19.5 to
41.4 mm] vs. 24.3 mm [range 15.7 to 36.7 mm],
respectively; p ¼ 0.11). There were no significant
differences in other gray-scale IVUS characteristics
(Supplemental Table 4). In both groups, virtual his-
tology fibroatheroma was the predominant type of
lesion (91.4% vs. 86.4%, respectively; p ¼ 0.54),
approximately 50% were VH-TCFA (57.1% vs. 47.0%,
respectively; p ¼ 0.33). There were no significantdifferences in overall plaque composition, defined as
percent of fibrous tissue, fibrofatty tissue, necrotic
core, or dense calcium, either over the whole plaque
or at the MLA (Table 1).
PSS IN NONCULPRIT LESIONS WITH MACE AT THE
PERI-MLA SEGMENTS. A total of 101 nonculprit pla-
ques (35 with MACE, 66 with no-MACE) were
analyzed, generating 8,182 VH-IVUS frames, all of
which underwent FEA to calculate mean PSS and PSS
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PSS Variation in PSS
VH-TCFA + PB ≥70%F
Heterogeneity index of PSS or variations in PSS for (A) all plaques, (B) VH-TCFAs, (C) VH-TCFA þ MLA #4 mm2, (D) plaques with
MLA #4 mm2, (E) plaques with PB $ 70% at the MLA and (F) VH-TCFA þ PB $70%. *p < 0.05. Abbreviations as in Figures 1 and 3.
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variations at systole and diastole (Figure 2A). PSS and
variations in PSS across the entire plaque length were
similar between the 2 groups, regardless of plaques
subtype (Supplemental Figure 1). However, PSS was
markedly heterogeneous across the whole plaque,
even over short distances (Figure 2B), reflecting small
changes in plaque composition at the luminal surface.
PSS and variations in PSS were increased in MACE
compared to those in the no-MACE groups in the peri-
MLA regions regardless of whether all plaques (PSS:
112.1  5.5 kPa vs. 90.4  3.3 kPa; p ¼ 0.001; variations
in PSS: 30.5  1.5 kPa vs. 24.5  0.9 kPa; p ¼ 0.001) or
only VH-TCFA plaques (PSS: 119.2  6.6 kPa vs.
95.8  5.0 kPa; p ¼ 0.005; variations in PSS:32.3  1.8 kPa vs. 25.9  1.4 kPa; p ¼ 0.004) were
examined (Figures 3A and 3B). PSS was also increased
in MACE compared to those in no-MACE plaques with
MLA #4 mm2 (PSS: 100.3  7.5 kPa vs. 83.6  2.7 kPa;
p ¼ 0.007; variations in PSS: 27.5  2.1 kPa vs.
22.6  0.7 kPa; p ¼ 0.007) (Figure 3C) and with
PB $70% at the MLA site, although this was of
borderline statistical significance (106.4  6.7 kPa vs.
90.1  5.2 kPa; p ¼ 0.05; variations in PSS: 29.1  1.9
vs. 24.4  1.4 kPa; p ¼ 0.05) (Figure 3D). PSS and
variations in PSS were also increased in the MACE
group when VH-TCFAs with an MLA #4 mm2 specif-
ically was examined (Figure 3E) but not VH-TCFA with
PB $70% (Figure 3F).
FIGURE 5 Time-to-Event Curves for MACE Rates According to Baseline Plaque Characteristics and PSS Group
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Follow-Up (Days)
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VH-TCFA + PB ≥70% + High PSS
VH-TCFA + PB ≥70% + Low PSS
Cumulative MACE probability for (A) all plaques, (B) VH-TCFAs, (C) plaques with MLA #4 mm2, (D) VH-TCFA þ MLA #4 mm2, (E) plaques with PB $70%
at the MLA, and (F) VH-TCFA þ PB $70% according to high or low PSS. All plaques ¼ 101 (100%); VH-TCFA ¼ 51 (50.5%); MLA #4 mm2 ¼ 47 (46.5%);
VH-TCFA þ MLA #4 mm2 ¼ 20 (19.8%); PB $70% at the MLA ¼ 55 (54.5%); VH-TCFA þ PB $70% ¼ 21 (20.8%). Abbreviations as in Figures 1 and 3.
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Heterogeneity in PSS and variations in PSS was
increased at the peri-MLA segment.
Substantial differences were observed in PSS along
the plaque length, even over short distances
(Figure 2B, Supplemental Figure 2). Therefore the
heterogeneity of PSS and variations in PSS in MACE
versus no-MACE plaques were examined using a
standard HI. Although heterogeneity of PSS or PSS
variations in all plaques were similar between the 2
groups (PSS HI: p ¼ 0.07; variations in PSS HI:
p ¼ 0.05) (Figure 4A), both parameters were markedly
greater in MACE VH-TCFAs (PSS HI: p ¼ 0.01; varia-
tions in PSS HI: p ¼ 0.02) (Figure 4B), and in
VH-TCFAs with MLA #4 mm2 (PSS HI: p ¼ 0.02; var-
iations in PSS HI: p ¼ 0.03) (Figure 4C). Heterogeneity
was similar in plaques with MLA #4 mm2 (Figure 4D),
PB $70% at the MLA site (Figure 4E), or VH-TCFA plus
PB $70% (Figure 4F) in both groups.
INCORPORATION OF PSS AND HETEROGENEITY
IN PSS IMPROVED PREDICTION OF MACE. In
PROSPECT, VH-TCFAs (4.9% vs. 1.3%; p ¼ 0.001),
plaques with MLA #4 mm2 (5.3% vs. 1.1%; p ¼ 0.001),
and those with PB $70% at the MLA site (9.6% vs.
1.2%; p ¼ 0.001) were more likely to lead to NCL
MACE. However, 45.5% of NCL MACE plaques had an
MLA >4 mm2, 54.5% had PB <70% at the MLA site,
and 49.0% of MACE occurred in non-VH-ThCFA pla-
ques (2) (Supplemental Figure 3). Therefore, PSS and
PSS heterogeneity were examined in an attempt to
improve the ability of baseline plaque features to
stratify coronary plaque risk.
ROC analysis was used first to identify the PSS and
heterogeneity in PSS cutoff thresholds that best pre-
dicted future MACE (Supplemental Figure 4).
Including PSS in plaque assessment markedly
improved the identification of nonculprit plaques
that led to MACE for all plaques (p ¼ 0.002)
(Figure 5A), for VH-TCFAs (p ¼ 0.03) (Figure 5B), for
plaques with MLA #4 mm2 (p ¼ 0.03) (Figure 5C), or
for VH-TCFA plaques with an MLA #4 mm2 (p ¼ 0.03)
(Figure 5D) but not plaques with PB $70% at the MLA
(p ¼ 0.12) (Figure 5E) or VH-TCFA plaques with a
PB $70% at the MLA (p ¼ 0.77) (Figure 5F).
Incorporating HI further improved the ability to
use PSS as a means of distinguishing between MACE
and no-MACE NCLs across a variety of plaque char-
acteristics including all plaques (p ¼ 0.001)
(Figure 6A), VH-TCFA plaques (p ¼ 0.001) (Figure 6B),
PB $70% at the MLA site (p ¼ 0.01) (Figure 6C),
MLA #4 mm2 (p ¼ 0.002) (Figure 6D), and VH-TCFA
plaques with an MLA #4 mm2 (p ¼ 0.004)
(Figure 6E) but not VH-TCFA plaques with a PB $70%
(p ¼ 0.36) (Figure 6F). Further analysis demonstratedacceptable positive predictive values for high PSS
and high HI across a variety of plaque subtypes
(Supplemental Appendix).
DISCUSSION
Both post-mortem and prospective VH-IVUS studies
have identified TCFA (or VH-TCFA) as the lesion most
likely to rupture (2,4,5,11). However, TCFAs are
frequent in patients with coronary artery disease
(2,12); they are present in patients with both stable
and unstable syndromes (13), and <10% actually lead
to MACE within several years. Furthermore, MACE
are not restricted to TCFAs, suggesting that factors
additional to plaque morphology are important in
determining which plaques act as precursors of future
events.
PSS is regulated by plaque composition, geometry,
luminal configuration, and hemodynamic factors (8),
and may contribute to plaque risk stratification. In
the VIVA study, PSS was increased in culprit plaques
of patients who presented with ACS versus those with
stable angina and in those that ruptured and led to
future MACE (8–10). Furthermore, the combination of
PSS estimates and IVUS provided results that were
superior to those of IVUS alone in identifying plaques
that led to MACE. However, VIVA was a small single-
center study in 170 patients without angiographic
confirmation of all MACE, and such findings require
confirmation in larger, multicenter cohorts. It is also
unclear whether there are PSS parameters that are
better discriminators of MACE than those studied in
VIVA.
The present study compared a cohort with NCL
MACE from the 697-patient multicenter PROSPECT
study with a propensity-matched control group (8).
Although PSS did not differ between the 2 groups
across the entire plaque length, significant differ-
ences were observed in the peri-MLA regions, sites
where plaque destabilization is most likely to occur
(14) (Central Illustration). More specifically, PSS and
variations in PSS were higher in MACE plaques
regardless of whether all plaques, VH-TCFAs, or pla-
ques with MLA #4 mm2 were examined. Both pa-
rameters were also increased in NCL with PB $70% at
the MLA, although this did not quite reach statistical
significance; which is not unexpected because the
propensity score matching process included only
plaques with PB $60 at the MLA site.
High PSS in the peri-MLA segments can lead to
plaque destabilization either by triggering rupture or
by increasing vulnerability through necrotic core
growth. Increased variations in PSS between systole
and diastole may also result in fibrous cap fatigue,
FIGURE 6 Time-to-Event Curves for MACE Rates According to Baseline Plaque Characteristics, PSS, and PSS Heterogeneity Index Groups
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CENTRAL ILLUSTRATION High PSS and High Heterogeneity in PSS Is Associated With Increased
Risk of Future MACE in VH-TCFA
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(A) VH-IVUS and its associated band plot in a VH-TCFA. (B) PSS, variations in PSS and heterogeneity index of PSS is increased in VH-TCFAs
with future MACE. (C) Incorporation of PSS and heterogeneity index in PSS allows the identification of VH-TCFAs that lead to MACE.
*p < 0.05. HI ¼ heterogeneity index; MACE ¼ major adverse cardiovascular events; PSS ¼ plaque structural stress; VH-TCFA ¼ virtual-
histology thin-cap fibroatheroma.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: PSS,
variations in PSS and longitudinal heterogeneity in
PSS is increased in the peri-MLA regions of plaques,
including VH-TCFA, which proceed to future MACE.
Incorporation of such biomechanical analysis improves
the ability of IVUS to identify high-risk plaques.
TRANSLATIONAL OUTLOOK: PSS, which may be
estimated from VH-IVUS images, has been proposed
as a mechanism that determines rupture in high-risk
regions. This study provides further evidence that PSS
and other associated features may better identify
plaques that cause future patient events, allowing
earlier and more aggressive treatment of relevant risk
factors.
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12further promoting plaque disruption. Heterogeneity
in PSS and variations in PSS in peri-MLA segments
were also increased in VH-TCFAs associated with
MACE versus those in no-MACE patients (Central
Illustration). This could be due to subtle differences in
plaque composition or luminal geometry or both,
which may result in points of fibrous cap weakness in
the longitudinal direction (as opposed to the axial
direction, hypothesized with increased variations in
PSS). Increased PSS heterogeneity in conjunction
with high PSS would therefore further promote pla-
que destabilization.
One aim of plaque imaging is to identify the subset
of plaques at highest risk of MACE, so that therapy
and monitoring can be adjusted according to prog-
nosis. This is particularly important for new treat-
ments such as PCSK9 inhibitor therapy (15) or
canakinumab therapy (16), which may be too expen-
sive for the entire population at risk. This study found
that PSS and HI calculations significantly improved
plaque risk stratification, an important consideration
when most plaques classified as high-risk by imaging
alone remain clinically silent (Central Illustration).
Indeed, there was divergence of the time-to-event
curves for both PSS and heterogeneity of PSS within
1 year of follow-up (Figures 4 and 5), which further
implicates PSS in plaque destabilization. As PSS, like
plaque morphology, can be highly dynamic over time,
the effects of high PSS and/or PSS heterogeneity on
plaque stability would be expected to occur closer to
the time of high stress.
Similar to PSS, endothelial shear stress (ESS) has
been shown recently to provide incremental risk
stratification of untreated coronary lesions beyond
IVUS plaque characterization (17). PSS describes the
stress located inside an atherosclerotic plaque and is
affected by vessel expansion and stretch by exposure
to arterial pressure, whereas ESS describes the par-
allel friction force exerted by blood flow on the
endothelial surface of the arterial wall. As PSS and
ESS refer to different biomechanical forces, it is
possible that the combination of ESS and PSS may
improve plaque risk stratification further. Ultimately
the combination of patient characteristics, plaque
morphology, and biomechanical and inflammation
plaque profiling may allow identification of those
NCLs that will proceed to MACE, thus allowing more
aggressive secondary prevention and also perhaps
earlier definitive treatment.
STUDY LIMITATIONS. First, PSS calculations were
applied retrospectively, and prospective studies
should be performed to confirm the additive value of
PSS and other PSS-related parameters in plaque risk
assessment. However, propensity score matchingensured that a well-matched control group was used
for comparison. Second, MACE in the PROSPECT
study were largely driven by hospitalization for pro-
gressive and unstable angina, and although this could
be due to plaque rupture with subsequent healing,
other forms of plaque destabilization or plaque
growth may be responsible. Third, PSS calculations
based on VH-IVUS are limited by the resolution and
ability of VH-IVUS to identify plaque components.
However, IVUS is the only intravascular imaging
modality to date with prospective clinical data.
Finally, the role of ESS was not investigated, which
can be important in a study where clinical events are
likely driven by plaque growth. Combined PSS and
ESS of the PROSPECT study would be of huge
interest.
CONCLUSIONS
PSS and variations in PSS in the peri-MLA regions
were increased in nonculprit plaques, leading to
MACE in the PROSPECT study across a variety of
plaque subtypes. Longitudinal heterogeneity in PSS
was also increased in plaques leading to MACE,
especially VH-TCFAs. Incorporation of PSS and het-
erogeneity in PSS improves the ability of IVUS to
predict MACE, suggesting that biomechanical
modeling may have a role in coronary atherosclerotic
plaque risk stratification.
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